Target Name: KRT17
NCBI ID: G3872
Review Report on KRT17 Target / Biomarker Content of Review Report on KRT17 Target / Biomarker
KRT17
Other Name(s): cytokeratin-17 | keratin 17 | Keratin-17 | PCHC1 | CK-17 | K17 | PC | PC2 | 39.1 | K1C17_HUMAN | Keratin 17 | Keratin, type I cytoskeletal 17 | keratin 17, type I | Cytokeratin-17

KRT17: A Potential Drug Target for Cancer, Regenerative Diseases and Autoimmune Disorders

KRT17 (Cytokeratin-17), also known as K17, is a protein that is expressed in a variety of tissues throughout the body, including the skin, hair, nails, and connective tissue. It is a member of the keratin family, which is a group of proteins that are responsible for the formation and maintenance of the hair and nails.

Recent studies have identified KRT17 as a potential drug target for the treatment of various diseases, including cancer, regenerative diseases, and autoimmune disorders. This is because KRT17 has been shown to play a role in the development and progression of these diseases, and may be able to provide insight into their underlying causes.

One of the key reasons for the potential of KRT17 as a drug target is its role in the development of cancer. Many studies have shown that KRT17 is highly expressed in various types of cancer, including breast, ovarian, and prostate cancer. Additionally, studies have shown that KRT17 is involved in the regulation of cell growth and division, which is a known risk factor for the development of cancer.

Another potential drug target for KRT17 is its role in regenerative diseases. KRT17 has been shown to be involved in the regulation of cell death and division, which is important for the growth and repair of tissues. This is particularly relevant in the treatment of regenerative diseases, such as blindness, where the loss of cells and tissues can lead to significant functional impairments.

In addition to its potential role in cancer and regenerative diseases, KRT17 has also been shown to be involved in the regulation of the immune system. This is important for the immune response, which is critical for the fight against infection and disease.

Overall, KRT17 is a protein that has the potential to be a drug target for the treatment of a variety of diseases. Its role in the development and progression of cancer, its involvement in regenerative diseases, and its role in the immune system make it an attractive target for researchers and clinicians alike. As more studies are conducted, it is likely that the potential benefits of KRT17 as a drug will become increasingly clear.

Protein Name: Keratin 17

Functions: Type I keratin involved in the formation and maintenance of various skin appendages, specifically in determining shape and orientation of hair (By similarity). Required for the correct growth of hair follicles, in particular for the persistence of the anagen (growth) state (By similarity). Modulates the function of TNF-alpha in the specific context of hair cycling. Regulates protein synthesis and epithelial cell growth through binding to the adapter protein SFN and by stimulating Akt/mTOR pathway (By similarity). Involved in tissue repair. May be a marker of basal cell differentiation in complex epithelia and therefore indicative of a certain type of epithelial 'stem cells'. Acts as a promoter of epithelial proliferation by acting a regulator of immune response in skin: promotes Th1/Th17-dominated immune environment contributing to the development of basaloid skin tumors (By similarity). May act as an autoantigen in the immunopathogenesis of psoriasis, with certain peptide regions being a major target for autoreactive T-cells and hence causing their proliferation

The "KRT17 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KRT17 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

KRT17P1 | KRT17P2 | KRT17P3 | KRT17P5 | KRT17P7 | KRT18 | KRT18P1 | KRT18P12 | KRT18P13 | KRT18P16 | KRT18P17 | KRT18P19 | KRT18P22 | KRT18P23 | KRT18P24 | KRT18P27 | KRT18P28 | KRT18P29 | KRT18P31 | KRT18P33 | KRT18P34 | KRT18P4 | KRT18P40 | KRT18P41 | KRT18P42 | KRT18P44 | KRT18P48 | KRT18P49 | KRT18P5 | KRT18P50 | KRT18P51 | KRT18P55 | KRT18P59 | KRT18P6 | KRT18P62 | KRT19 | KRT19P2 | KRT19P3 | KRT2 | KRT20 | KRT222 | KRT23 | KRT24 | KRT25 | KRT26 | KRT27 | KRT28 | KRT3 | KRT31 | KRT32 | KRT33A | KRT33B | KRT34 | KRT35 | KRT36 | KRT37 | KRT38 | KRT39 | KRT4 | KRT40 | KRT42P | KRT5 | KRT6A | KRT6B | KRT6C | KRT7 | KRT7-AS | KRT71 | KRT72 | KRT73 | KRT73-AS1 | KRT74 | KRT75 | KRT76 | KRT77 | KRT78 | KRT79 | KRT8 | KRT80 | KRT81 | KRT82 | KRT83 | KRT84 | KRT85 | KRT86 | KRT87P | KRT89P | KRT8P10 | KRT8P11 | KRT8P12 | KRT8P14 | KRT8P16 | KRT8P17 | KRT8P18 | KRT8P22 | KRT8P23 | KRT8P25 | KRT8P26 | KRT8P29 | KRT8P3